Market revenue in 2023 | USD 211.0 million |
Market revenue in 2030 | USD 292.6 million |
Growth rate | 4.8% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 63.84% in 2023. Horizon Databook has segmented the UK pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of sophisticated healthcare infrastructure, collaborations between key players, and the launch of novel products are anticipated to contribute to market growth in the UK. Government support & initiatives are expected to further propel the country’s pancreatic cancer diagnostics market in the coming decade.
Commercial partnerships between the government and key players for routine use of MCED tests in the country are likely to propel market growth. For instance, in November 2020, GRAIL entered into a commercial partnership with the UK government for a blood test. This agreement was expected to enhance the company’s position in the market.
Government bodies, such as the NHS, are undertaking measures to promote the usage of these tests, make them cost-effective & available to everyone, save time, and reduce the risk of complications. However, reimbursement scenarios and stringent regulatory policies may impede market growth over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the UK pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into UK pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account